Relmada Therapeutics (RLMD) Capital Expenditures (2014 - 2019)

Relmada Therapeutics (RLMD) has 6 years of Capital Expenditures data on file, last reported at $84.8 million in Q4 2019.

• Capital Expenditures for Q4 2019 came in at $84.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $84.9 million (changed N/A YoY), and the FY2020 annual result was $182.1 million, up 114.56% from the prior year.
• Capital Expenditures climbed to $84.8 million in Q4 2019 per RLMD's latest filing, from $9800.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $84.8 million in Q4 2019 and troughed at $1310.0 in Q3 2015.
• A 5-year average of $6.6 million and a median of $9800.0 in 2018 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2015 and 2016: Capital Expenditures jumped 7204.54% in 2015, then slumped 99.49% in 2016.
• A 5-year view of Capital Expenditures shows it stood at $474795.0 in 2015, then tumbled by 99.49% to $2434.0 in 2016, then grew by 6.45% to $2591.0 in 2017, then soared by 278.23% to $9800.0 in 2018, then surged by 865708.14% to $84.8 million in 2019.
• Business Quant data shows RLMD's Capital Expenditures at $84.8 million in Q4 2019, $9800.0 in Q2 2018, and $2591.0 in Q3 2017.